Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling.

Autor:	Fields JK; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA., Gyllenbäck EJ; Cantargia AB, Lund, Sweden., Bogacz M; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA., Obi J; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA., Birkedal GS; Cantargia AB, Lund, Sweden., Sjöström K; Innovagen AB, Lund, Sweden., Maravillas K; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA., Grönberg C; Cantargia AB, Lund, Sweden., Rattik S; Cantargia AB, Lund, Sweden., Kihn K; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA., Flowers M; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA., Smith AK; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA., Hansen N; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Fioretos T; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Huyhn C; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA., Liberg D; Cantargia AB, Lund, Sweden., Deredge D; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA., Sundberg EJ; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: eric.sundberg@emory.edu.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2024 May 28; Vol. 43 (5), pp. 114099. Date of Electronic Publication: 2024 Apr 17.
DOI:	10.1016/j.celrep.2024.114099
Abstrakt:	Interleukin-1 (IL-1)-family cytokines are potent modulators of inflammation, coordinating a vast array of immunological responses across innate and adaptive immune systems. Dysregulated IL-1-family cytokine signaling, however, is involved in a multitude of adverse health effects, such as chronic inflammatory conditions, autoimmune diseases, and cancer. Within the IL-1 family of cytokines, six-IL-1α, IL-1β, IL-33, IL-36α, IL-36β, and IL-36γ-require the IL-1 receptor accessory protein (IL-1RAcP) as their shared co-receptor. Common features of cytokine signaling include redundancy of signaling pathways, sharing of cytokines and receptors, pleiotropy of the cytokines themselves, and multifaceted immune responses. Accordingly, targeting multiple cytokines simultaneously is an emerging therapeutic strategy and can provide advantages over targeting a single cytokine pathway. Here, we show that two monoclonal antibodies, CAN10 and 3G5, which target IL-1RAcP for broad blockade of all associated cytokines, do so through distinct mechanisms and provide therapeutic opportunities for the treatment of inflammatory diseases. Competing Interests: Declaration of interests E.J.G., G.S.B., C.G., S.R., and D.L. are employees of Cantargia AB (Medicon Village, Lund, Sweden). K.S. is an employee of Innovagen AB (Lund, Sweden). E.J.G, G.S.B., K.S., C.G., S.R., T.F., and D.L. are shareholders of Cantargia AB. Cantargia AB is the owner of the intellectual property rights for CAN10 and 3G5 for use in the treatment of autoinflammatory and autoimmune diseases. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu